Clinical trials: Non-Communicable Chronic Diseases
HCV Infection
Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice
This study will collect and evaluate information on the safety and efficacy of Sovaldi-based regimens in routine clinical practice in Mexico.
- Trial name
- NCT02783976
- Testing
- Sovaldi
- Where
- 6 sites in Mexico
- Volunteers
- 25 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
Residual Histological Disease Across Treatment Pathways in Chronic Hepatitis B
This retrospective, two-center observational study evaluates contemporary non-biopsy treatment pathways in treatment-naïve adults with chronic hepatitis B who underwent liver biopsy in routine clinical practice.
- Trial name
- CHB-PATH (NCT07843446)
- Where
- Turkey (Türkiye)
- Volunteers
- 1,201 people
- Sponsor
- Istanbul Medeniyet University
Chronic Non-communicable Diseases, Cardiovascular Diseases
RegiStry Of the multiFaceted medIcal cenTer
This study is a prospective medical registry (the SOFIT Registry) that enrolls all patients hospitalized in various departments of the Tula Regional Clinical Hospital in 2021.
- Conditions
- Chronic Non-communicable Diseases, Cardiovascular Diseases, COVID-19, Multimorbidity
- Trial name
- SOFIT (NCT06803862)
- Where
- 2 sites in Russia
- Volunteers
- 21,783 people
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
Chronic Hepatitis C Infection
A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before
This is a study to evaluate the efficacy and safety of three experimental drugs compared with telaprevir (a licensed product) in people with hepatitis C virus infection who have not had treatment before.
- Trial name
- MALACHITE 1 (NCT01854697)
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin, Telaprevir
- Volunteers
- 311 people
- Sponsor
- AbbVie
Hepatitis B Virus (HBV)
The Impact of Treatment for Chronic Hepatitis B Virus on Non-clinical Harms
The goal of this qualitative study is to explore the impact of antiviral treatment, or none, for chronic hepatitis B virus on the non-clinical (social) harms experienced by migrant populations living in the UK.
- Trial name
- B-SOCIAL (NCT07053449)
- Volunteers
- 30 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Hepatitis C, Liver Disease
Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option
The primary purpose of this study is to evaluate the pharmacodynamic (i.e. hepatitis C virus (HCV) viral load), pharmacokinetic and safety profiles between two treatment groups receiving different doses of DEB025 in combination…
- Trial name
- NCT02094443
- Testing
- Alisporivir, Ribavirin
- Where
- 16 sites in United States, France
- Volunteers
- 52 people
- Sponsor
- Debiopharm International SA
Hepatitis C Virus Infection, Compensated Advanced Chronic Liver Disease
Non-Invasive Risk Stratification for Hepatocellular Carcinoma in HCV-Related Compensated Advanced Chronic Liver Disease Following Sustained Virological Response: Validation of the aMAP Score
This retrospective cohort study evaluated the performance of non-invasive risk scores for predicting de novo hepatocellular carcinoma in adults with hepatitis C virus-related compensated advanced chronic liver disease who…
- Conditions
- Hepatitis C Virus Infection, Compensated Advanced Chronic Liver Disease, Hepatocellular Carcinoma (HCC)
- Trial name
- HCV-aMAP (NCT07687758)
- Testing
- Non-invasive Risk Score Assessment
- Where
- Thailand
- Volunteers
- 571 people
- Sponsor
- Siriraj Hospital
Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic
To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients
A phase II study to evaluate the efficacy and safety in TG-2349 combination with DAG181 (± Ribavirin) in treatment naïve subjects with chronic hepatic C virus genotype I infection.
- Conditions
- Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic, Cirrhosis, Treatment naïve
- Trial name
- NCT03593447
- Testing
- non-cirrhotic subjects. low TG-2349+ low DAG181+Ribavirin, non-cirrhotic subjects. high TG-2349+ high DAG181+Ribavirin, non-cirrhotic subjects. low TG-2349+ low DAG181
- Where
- China
- Volunteers
- 133 people
- Sponsor
- Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
Chronic Hepatitis C
Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C
Study the effectiveness of telaprevir (VX-950) in combination with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a) and Ribavirin (RBV) in reducing plasma hepatitis C virus (HCV) ribonucleic acid (RNA) levels
- Trial name
- NCT00336479
- Testing
- Telaprevir, Ribavirin, Pegylated Interferon Alfa 2a
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 263 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Diabetes Mellitus, Hypertension
The Long-term Spill-over Impact of COVID-19 on Health and Healthcare of People With Non-communicable Diseases
Objectives and aim: To evaluate the long-term spill-over (indirect) effect of Coronavirus disease (COVID-19) on health outcomes and healthcare utilization among people with non-communicable diseases and without COVID-19.
- Conditions
- Diabetes Mellitus, Hypertension, Cancer, Cardiovascular Diseases
- Trial name
- NCT05248412
- Testing
- COVID-19 outbreaks
- Where
- China
- Volunteers
- 250,000 people
- Sponsor
- The University of Hong Kong
Hepatitis C Virus (HCV)
A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection
A Phase 3b, open-label, multicenter study to evaluate the efficacy and safety of glecaprevir/pibrentasvir for an 8- or 12-week treatment duration in participants with chronic hepatitis C virus (HCV) genotype (GT) 5 or 6…
- Trial name
- ENDURANCE-5 6 (NCT02966795)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 25 sites in United States, Australia and 7 more
- Volunteers
- 84 people
- Sponsor
- AbbVie
Hepatitis C
Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy
The primary objectives of this study are to compare the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed dose combination (FDC) for 8 weeks with that of SOF/VEL FDC for…
- Trial name
- POLARIS-2 (NCT02607800)
- Testing
- SOF/VEL/VOX, SOF/VEL
- Where
- 93 sites in United States, Australia and 6 more
- Volunteers
- 943 people
- Sponsor
- Gilead Sciences
Gestational Diabetes Mellitus (GDM), Non-communicable Chronic Diseases
Long-term Evaluation of Gestational Endocrine & Metabolic Dynamics
Gestational diabetes mellitus (GDM) is the most common complication and metabolic disorder during pregnancy, with clear risks to both the mother and fetus.
- Trial name
- LEGEND (NCT07119177)
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Yang ZHANG
Cardiovascular Diseases (CVD), Type 2 Diabetes
Epigenetics and NCD Prevention in Kazakhstan: Personalized Approaches and Biological Age Prediction
This study aims to enhance personalized and preventive care for non-communicable diseases (NCDs) in Kazakhstan by examining epigenetic factors, predicting biological age and reproductive function using machine learning, and…
- Conditions
- Cardiovascular Diseases (CVD), Type 2 Diabetes, Chronic Respiratory Diseases, Obesity (Disorder)
- Trial name
- NCT06953180
- Testing
- Genetic: DNA analysis
- Where
- Kazakhstan
- Volunteers
- 6,720 people, healthy volunteers welcome
- Sponsor
- Asfendiyarov Kazakh National Medical University
Non-alcoholic Fatty Liver Disease, Renal Function Impairment
Analysis of Renal Impairment Characteristics and High-Risk Factors in Chronic Hepatitis B Patients on Long-Term Oral Nucleos(t)Ide Analogues
This is a single-center retrospective observational study. A total of 300 patients with non-alcoholic fatty liver disease treated in our hospital will be included.
- Trial name
- NCT07730905
- Testing
- Long-term oral nucleos(t)ide analogs antiviral therapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Foshan Hospital of Traditional Chinese Medicine
Chronic Hepatitis B
Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude
Open-labeled, Prospective, Randomized, Multi-center, Interventional, Phase IV study.
- Trial name
- NCT02523547
- Testing
- Cavir, Baraclude
- Where
- South Korea
- Volunteers
- 134 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Chronic Hepatitis C Infection
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
The purpose of this study is to evaluate the safety and efficacy of ABT-450, ritonavir and ABT-267 (ABT-450/r/ABT-267; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) co-administered with ribavirin (RBV)…
- Trial name
- NCT01715415
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin
- Volunteers
- 395 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hepatitis C, Chronic
A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)
This open-label, non-comparative study will assess the safety and tolerability of individualized combination therapy with Copegus (ribavirin) and Pegasys (peginterferon alfa-2a) in patients with chronic hepatitis C.
- Trial name
- NCT01296971
- Testing
- peginterferon alfa-2a [Pegasys], ribavirin [Copegus]
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)
This is an uncontrolled, non-randomized, open-label, multinational study designed to evaluate the efficacy and safety of PegIntron plus Rebetol in subjects with chronic hepatitis C.
- Trial name
- NCT00441584
- Testing
- PegIntron (peginterferon alfa-2b), Rebetol (ribavirin)
- Volunteers
- 117 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
Debio 025 (alisporivir) is an oral cyclophilin inhibitor with a new mechanism of action demonstrating potent anti-hepatitis C virus (HCV) activity in pre-clinical models and patients.
- Trial name
- NCT00537407
- Testing
- Debio 025, Peg-IFNα2a, Ribavirin
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Debiopharm International SA